130 related articles for article (PubMed ID: 9137491)
1. Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: clinical and therapeutical significance.
Bodey B; Bodey B; Gröger AM; Luck JV; Siegel SE; Taylor CR; Kaiser HE
Anticancer Res; 1997; 17(2B):1311-8. PubMed ID: 9137491
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression.
Bodey B; Taylor CR; Siegel SE; Kaiser HE
Anticancer Res; 1995; 15(6B):2461-8. PubMed ID: 8669809
[TBL] [Abstract][Full Text] [Related]
3. Cross-reactivity of C219 anti-p170(mdr-1) antibody with p185(c-erbB2) in breast cancer cells: cautions on evaluating p170(mdr-1).
Liu B; Sun D; Xia W; Hung MC; Yu D
J Natl Cancer Inst; 1997 Oct; 89(20):1524-9. PubMed ID: 9337349
[TBL] [Abstract][Full Text] [Related]
4. A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections.
Moran E; Larkin A; Doherty G; Kelehan P; Kennedy S; Clynes M
J Clin Pathol; 1997 Jun; 50(6):465-71. PubMed ID: 9378810
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of p53 protein overexpression in primary human osteosarcomas.
Bodey B; Gröger AM; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1997; 17(1A):493-8. PubMed ID: 9066701
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia.
Michieli M; Damiani D; Geromin A; Michelutti A; Fanin R; Raspadori D; Russo D; Visani G; Dinota A; Pileri S
Eur J Haematol; 1992 Feb; 48(2):87-92. PubMed ID: 1347749
[TBL] [Abstract][Full Text] [Related]
7. The expression of drug resistance gene products during the progression of human prostate cancer.
Sullivan GF; Amenta PS; Villanueva JD; Alvarez CJ; Yang JM; Hait WN
Clin Cancer Res; 1998 Jun; 4(6):1393-403. PubMed ID: 9626455
[TBL] [Abstract][Full Text] [Related]
8. The role of apoptosis in normal ontogenesis and solid human neoplasms.
Kaiser HE; Bodey B
In Vivo; 2000; 14(6):789-803. PubMed ID: 11204498
[TBL] [Abstract][Full Text] [Related]
9. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI
Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646
[TBL] [Abstract][Full Text] [Related]
10. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
11. [The clinical significance of lung resistance-related protein gene (lrp), multidrug resistance-associated protein gene (mrp) and mdr-1/p170 expression in acute leukemia].
Zhao Y; Yu L; Lou F; Wang Q; Pu J; Zhou Q
Zhonghua Nei Ke Za Zhi; 1999 Nov; 38(11):760-3. PubMed ID: 11798719
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of multidrug resistance in cancer chemotherapy.
Nooter K; Stoter G
Pathol Res Pract; 1996 Jul; 192(7):768-80. PubMed ID: 8880878
[TBL] [Abstract][Full Text] [Related]
13. Quantitative immunocytochemical assays of P-glycoprotein in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators.
Charpin C; Vielh P; Duffaud F; Devictor B; Andrac L; Lavaut MN; Allasia C; Horschowski N; Piana L
J Natl Cancer Inst; 1994 Oct; 86(20):1539-45. PubMed ID: 7932810
[TBL] [Abstract][Full Text] [Related]
14. Expression of multidrug resistance gene (MDR-1) in human normal leukocytes.
Damiani D; Michieli M; Michelutti A; Geromin A; Raspadori D; Fanin R; Savignano C; Giacca M; Pileri S; Mallardi F
Haematologica; 1993; 78(1):12-7. PubMed ID: 8098310
[TBL] [Abstract][Full Text] [Related]
15. Biophysical characterization of MDR breast cancer cell lines reveals the cytoplasm is critical in determining drug sensitivity.
Coley HM; Labeed FH; Thomas H; Hughes MP
Biochim Biophys Acta; 2007 Apr; 1770(4):601-8. PubMed ID: 17270349
[TBL] [Abstract][Full Text] [Related]
16. Cancer chemotherapy does not enhance MDR-associated 170 kd glycoprotein expression in normal blood mononuclear cells.
Geromin A; Michieli M; Damiani D; Michelutti A; Vigevani E; Signor M; Fanin R; Baccarani M
Haematologica; 1992; 77(6):470-2. PubMed ID: 1363234
[TBL] [Abstract][Full Text] [Related]
17. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer.
Kovalev AA; Tsvetaeva DA; Grudinskaja TV
Exp Oncol; 2013 Dec; 35(4):287-90. PubMed ID: 24382439
[TBL] [Abstract][Full Text] [Related]
18. The human multidrug resistance gene (MDR-1): immunocytochemical detection of its expression in oral SCC.
Lo Muzio L; Staibano S; Pannone G; Mignogna MD; Serpico R; Rubini C; Fioroni M; Fanali S; Piattelli A
Anticancer Res; 2000; 20(5A):2891-7. PubMed ID: 11062698
[TBL] [Abstract][Full Text] [Related]
19. MDR-related P170-glycoprotein modulates cytotoxic activity of homoharringtonine.
Russo D; Michelutti A; Melli C; Damiani D; Michieli MG; Candoni A; Zhou DC; Marie JP; Zittoun R; Baccarani M
Leukemia; 1995 Mar; 9(3):513-6. PubMed ID: 7885049
[TBL] [Abstract][Full Text] [Related]
20. Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it.
Hait WN; Yang JM
Semin Oncol; 2005 Dec; 32(6 Suppl 7):S16-21. PubMed ID: 16360718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
